南昌看焦虑症症去那的中医院好南昌市第十二医院治精神科正不正规评价怎么样,南昌哪家治疗幻视医院比较好,南昌哪几家医院有看焦虑症,治幻想到那个医院好南昌,南昌治疗抑郁的办法哪个有效,南昌第十二医院口碑好吗正规吗,南昌治疗幻视那个医院好

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

MOSCOW, Aug. 26 (Xinhua) -- Russia will carry out two unmanned test launches of Soyuz carrier rockets in the coming fall before delivering crews to the International Space Station (ISS), local media reported on Friday.Citing a source, RIA Novosti news agency said that one of the Soyuz rockets was scheduled to send a new Progress M-13M space freighter to the ISS.On Wednesday, a Progress M-12M cargo ship failed to reach the orbit after the engine of a Soyuz-U carrier rocket turned off during the ascend. Soon after the accident, Russia announced it will temporarily ground all Soyuz rockets.Due to the accident, Russian space authorities have put off Thursday's launch of a Soyuz-2 carrier rocket from the Plesetsk Space Center in northern Russia and a launch of a manned space ship from Baikonur space center in Kazakhstan.After the retirement of the U.S. shuttle fleet, Russia's Soyuz spacecrafts have become the only way for astronauts to reach the ISS until at least the middle of the decade.

ULAN BATOR, Aug. 2 (Xinhua) -- The Mongolian government has confirmed equine influenza, a disease that mainly affects horses, broke out in 14 provinces.The government's news office announced the confirmation Tuesday after suspected cases were recently discovered in 18 provinces of the country, where horses still play a key role.According to a Mongolian government report, Mongolian Vice Premier M. Enkhbold called a state emergency situation committee meeting on Monday to respond to the epidemic.Millions of horses will need to be vaccinated, given cases of the disease have been discovered in all but three provinces -- Bayan-Ulgii, Zavkhan and Umnugobi.Equine influenza usually broke out in spring and fall, said an official of the Mongolian veterinarian and breeding bureau. He urged vaccination to be carried out as soon as possible.Mongolia has experienced several equine influenza outbreaks in the past few decades. Outbreaks in Khovd province in 2007 and 2008 caused huge losses to the local livestock industry.Animal husbandry is a dominant factor in the agriculture sector of Mongolia, which has more than 40 million livestock, 2 million of which are horses.

WASHINGTON, Aug. 2 (Xinhua) -- A new study has identified the recent emergence of a multidrug-resistant strain of Salmonella that has a high level resistance to ciprofloxacin, a common treatment for severe Salmonella infections. The study was published on-line Tuesday in The Journal of Infectious Diseases.Francois-Xavier Weill at the Pasteur Institute in France and colleagues studied information from national surveillance systems in France, England and Wales, Denmark, and the United States. The data showed that a multidrug-resistant strain of Salmonella, known as S. Kentucky, infected 489 patients in France, England and Wales, and Denmark between 2000 and 2008. In addition, researchers reported that the first infections were acquired mainly in Egypt between 2002 and 2005, while since 2006 the infections have also been acquired in various parts of Africa and the Middle East. The absence of reported international travel in approximately 10 percent of the patients suggests that infections may have also occurred in Europe through consumption of contaminated imported foods or through secondary contaminations.In this study, multidrug-resistant S. Kentucky was isolated from chickens and turkeys from Ethiopia, Morocco, and Nigeria, suggesting that poultry is an important agent for infection. The common use of fluoroquinolones in chicken and turkey production in Nigeria and Morocco may have contributed to this rapid spread, according to the researchers.This study highlights the importance of public health surveillance in a global food system. The investigators reported that they will continue to monitor this multidrug-resistant strain as well as help strengthen the capacities of national and regional laboratories in the surveillance of Salmonella and other major foodborne pathogens through the World Health Organization Global Foodborne Infections Network.Salmonella infection represents a major public health problem worldwide. An estimated 1.7 million such infections occur in North America each year. More than 1.6 million cases were reported between 1999 and 2008 in 27 European countries. Although most Salmonella infections produce only mild gastroenteritis, elderly and immunocompromised patients are especially at risk for life- threatening infections. These cases are typically treated with antimicrobials called fluoroquinolones, such as ciprofloxacin.